Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merrick, D. T.
Right arrow Articles by Hirsch, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merrick, D. T.
Right arrow Articles by Hirsch, F. R.
Related Collections
Right arrow Oncogenesis
Right arrow Oncogenesis: Clinical Models
Right arrow Oncogenesis: Intraepithelial Neoplasia/Premalignancy
Clinical Cancer Research Vol. 12, 2281-2288, April 2006
© 2006 American Association for Cancer Research


Cancer Prevention

Analysis of c-ErbB1/Epidermal Growth Factor Receptor and c-ErbB2/HER-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer

Daniel T. Merrick1,2, John Kittelson1, Ralph Winterhalder3, Georgia Kotantoulas4, Steen Ingeberg5, Robert L. Keith1,2, Timothy C. Kennedy1, York E. Miller1,2, Wilbur A. Franklin1 and Fred R. Hirsch1

Authors' Affiliations: 1 Departments of Pathology and Medicine/Pulmonary, University of Colorado Cancer Center, 2 Departments of Pathology and Medicine/Pulmonary, Denver Veteran's Administration Medical Center, Denver, Colorado, 3 University Hospital, Zurich, Switzerland, 4 Athens Chest Hospital, Center of Respiratory and Critical Care Medicine, Athens, Greece, and 5 Naestved Hospital, Department of Medicine, Naestved, Denmark

Requests for reprints: Fred R. Hirsch, University of Colorado Health Sciences Center, P.O. Box 6511, Mail Stop 8111, Aurora, CO 80045. Phone: 303-399-8020; Fax: 303-393-5036; E-mail: Daniel.Merrick{at}med.va.gov.

Purpose: Lung cancer is preceded by a premalignant phase during which intervention could decrease associated morbidity and mortality. Molecular characterization of factors involved in controlling progression of bronchial dysplasias will provide markers of premalignant change and identify targets for chemoprevention.

Experimental Design: Immunohistochemical analysis of epidermal growth factor receptor (EGFR; c-ErbB1/EGFR), HER-2/neu (c-ErbB2/HER-2), Ki-67, and minichromosome maintenance protein 2 (MCM2) expression in bronchial dysplasia was undertaken to characterize molecular alterations associated with the progression of these lesions in 268 bronchoscopically obtained biopsies from 134 subjects.

Results: Analysis of biopsies with the most severe diagnosis from each subject showed a linear relationship between increasing marker expression and severity of dysplastic change for EGFR (P < 0.001), Ki-67 (P < 0.001), and MCM2 (P = 0.001) but not HER-2 (P = 0.102). Increased expression of either EGFR or HER-2 was associated with increased levels of Ki-67 and MCM2 expression, and combined overexpression of these receptors was associated with the highest levels of proliferation, suggesting a synergistic effect. Finally, the lack of an associated trend toward increased EGFR expression when comparing the worst and best biopsies within each subject indicated a potential field effect in the induction of EGFR expression.

Conclusions: The results suggest a prominent role for EGFR overexpression in the development and progression of bronchial dysplasia and provide rationale for exploring inhibition of EGFR signaling in lung cancer chemoprevention.




This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
X. Tang, M. Varella-Garcia, A. C. Xavier, E. Massarelli, N. Ozburn, C. Moran, and I. I. Wistuba
Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas
Cancer Prevention Research, August 1, 2008; 1(3): 192 - 200.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. N. Hittelman, D. D. Liu, J. M. Kurie, R. Lotan, J. S. Lee, F. Khuri, H. Ibarguen, R. C. Morice, G. Walsh, J. A. Roth, et al.
Proliferative Changes in the Bronchial Epithelium of Former Smokers Treated With Retinoids
J Natl Cancer Inst, November 7, 2007; 99(21): 1603 - 1612.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
Y. E. Miller, P. Blatchford, D. S. Hyun, R. L. Keith, T. C. Kennedy, H. Wolf, T. Byers, P. A. Bunn Jr., M. T. Lewis, W. A. Franklin, et al.
Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2425 - 2431.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.